Transaction in Own Shares

PureTech Health PLC
09 November 2023
 

9 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

8 November 2023



Number of ordinary shares purchased:

44,412



Highest price paid per share:

165.60p



Lowest price paid per share:

160.40p



Volume weighted average price paid per share:

163.97p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,194,872 ordinary shares in treasury and has 273,273,287 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,273,287 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

08/11/2023

08:15:00

182

160.6

CHIX

00377565908TRLO0.1.1

08/11/2023

08:15:00

91

160.6

CHIX

00377565909TRLO0.1.1

08/11/2023

08:15:10

359

160.6

XLON

00377565937TRLO0.1.1

08/11/2023

08:18:03

86

160.6

CHIX

00377566493TRLO0.1.1

08/11/2023

08:19:29

221

160.4

AQXE

00377566733TRLO0.1.1

08/11/2023

11:08:58

51

162

XLON

00377593908TRLO0.1.1

08/11/2023

11:08:58

221

162

AQXE

00377593909TRLO0.1.1

08/11/2023

11:08:58

221

162

AQXE

00377593910TRLO0.1.1

08/11/2023

11:08:58

359

162

BATE

00377593912TRLO0.1.1

08/11/2023

11:08:58

1026

162

XLON

00377593911TRLO0.1.1

08/11/2023

11:08:58

30

162

CHIX

00377593913TRLO0.1.1

08/11/2023

11:08:58

359

162

CHIX

00377593914TRLO0.1.1

08/11/2023

11:08:58

718

162

BATE

00377593915TRLO0.1.1

08/11/2023

11:08:58

329

162

CHIX

00377593916TRLO0.1.1

08/11/2023

13:33:11

1398

163

XLON

00377611678TRLO0.1.1

08/11/2023

13:33:11

9303

163

XLON

00377611679TRLO0.1.1

08/11/2023

13:39:04

1436

164

XLON

00377612455TRLO0.1.1

08/11/2023

13:50:59

495

163.6

XLON

00377614045TRLO0.1.1

08/11/2023

13:50:59

582

163.6

XLON

00377614046TRLO0.1.1

08/11/2023

13:51:05

221

163.2

AQXE

00377614060TRLO0.1.1

08/11/2023

13:51:05

1795

163.2

CHIX

00377614062TRLO0.1.1

08/11/2023

13:51:05

718

163.2

BATE

00377614061TRLO0.1.1

08/11/2023

13:51:05

271

163.2

XLON

00377614063TRLO0.1.1

08/11/2023

14:42:42

2747

165

XLON

00377627725TRLO0.1.1

08/11/2023

14:42:42

3500

165

XLON

00377627726TRLO0.1.1

08/11/2023

15:33:06

221

165.6

AQXE

00377651038TRLO0.1.1

08/11/2023

15:33:06

359

165.6

BATE

00377651039TRLO0.1.1

08/11/2023

15:33:06

359

165.6

CHIX

00377651040TRLO0.1.1

08/11/2023

15:49:40

359

165.4

CHIX

00377658926TRLO0.1.1

08/11/2023

15:49:40

145

165.4

CHIX

00377658927TRLO0.1.1

08/11/2023

15:51:17

359

165.2

BATE

00377659755TRLO0.1.1

08/11/2023

15:51:17

2686

165

XLON

00377659756TRLO0.1.1

08/11/2023

15:51:17

1405

165

XLON

00377659757TRLO0.1.1

08/11/2023

15:51:17

107

165

XLON

00377659758TRLO0.1.1

08/11/2023

15:51:17

1200

165

XLON

00377659759TRLO0.1.1

08/11/2023

15:51:20

221

164.2

AQXE

00377659829TRLO0.1.1

08/11/2023

16:06:16

359

164.4

XLON

00377665943TRLO0.1.1

08/11/2023

16:06:51

27

164.4

XLON

00377666261TRLO0.1.1

08/11/2023

16:06:51

24

164.4

XLON

00377666262TRLO0.1.1

08/11/2023

16:06:51

75

164.4

XLON

00377666263TRLO0.1.1

08/11/2023

16:06:51

11

164.4

XLON

00377666265TRLO0.1.1

08/11/2023

16:06:51

62

164.4

XLON

00377666264TRLO0.1.1

08/11/2023

16:07:45

78

164.4

XLON

00377666990TRLO0.1.1

08/11/2023

16:07:45

105

164.4

XLON

00377666989TRLO0.1.1

08/11/2023

16:08:16

725

164

XLON

00377667186TRLO0.1.1

08/11/2023

16:11:02

8

164.4

CHIX

00377668532TRLO0.1.1

08/11/2023

16:14:22

493

165.2

XLON

00377670227TRLO0.1.1

08/11/2023

16:14:22

1111

165.2

XLON

00377670228TRLO0.1.1

08/11/2023

16:14:24

110

165.2

CHIX

00377670234TRLO0.1.1

08/11/2023

16:14:36

74

165.2

XLON

00377670320TRLO0.1.1

08/11/2023

16:14:42

307

165.2

CHIX

00377670378TRLO0.1.1

08/11/2023

16:15:44

359

165

BATE

00377670893TRLO0.1.1

08/11/2023

16:19:30

1157

164.6

XLON

00377673400TRLO0.1.1

08/11/2023

16:19:30

2359

164.6

XLON

00377673401TRLO0.1.1

08/11/2023

16:19:30

673

164.4

XLON

00377673402TRLO0.1.1

08/11/2023

16:19:31

643

165.2

CHIX

00377673412TRLO0.1.1

08/11/2023

16:19:31

110

165.2

CHIX

00377673413TRLO0.1.1

08/11/2023

16:19:32

114

164

BATE

00377673416TRLO0.1.1

08/11/2023

16:23:20

65

165.2

CHIX

00377675757TRLO0.1.1

08/11/2023

16:23:20

98

164

TRQX

00377675758TRLO0.1.1

08/11/2023

16:29:17

359

165.2

CHIX

00377679228TRLO0.1.1

08/11/2023

16:29:50

1

165.2

CHIX

00377679735TRLO0.1.1

08/11/2023

16:29:50

255

165.2

CHIX

00377679736TRLO0.1.1

08/11/2023

16:29:51

151

165.2

CHIX

00377679753TRLO0.1.1

08/11/2023

16:29:51

359

165.2

CHIX

00377679754TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings